Sickle Cell Disease: Voxelotor, Crizanlizumab, and Gene Therapy

Gene Therapy: Lovotibeglogene and Exagamglogene Autotemcel

Lovotibeglogene autotemcel (lovo-cel, Lyfgenia) uses lentiviral vector gene addition to produce anti-sickling hemoglobin (HbAT87Q). In the Phase 3 trial, 88% of evaluable patients achieved VOC-free status for at least 12 consecutive months post-infusion, with total hemoglobin of 11-14 g/dL[5]. Exagamglogene autotemcel (exa-cel, Casgevy) uses CRISPR-Cas9 gene editing to reactivate fetal hemoglobin production by disrupting BCL11A. In pivotal data, 97% of evaluable patients were VOC-free for at least 12 consecutive months, with HbF levels of 40-50%[6]. Both require myeloablative conditioning with busulfan, carrying risks of infertility, secondary malignancy (requiring cancer surveillance), and prolonged cytopenias.

Patient Selection for Gene Therapy

Gene therapy candidates are patients aged 12 and older with severe SCD characterized by recurrent VOCs (4 or more per year), acute chest syndrome, or significant end-organ damage despite optimized conventional therapy. Cost (exceeding $2 million), limited manufacturing capacity, and the requirement for specialized transplant centers remain major access barriers. Patients must weigh the potential for functional cure against conditioning-related risks, including a small but non-zero risk of myelodysplasia and leukemia observed with lentiviral-based approaches. Allogeneic hematopoietic stem cell transplant from matched sibling donors remains an established curative option with greater than 90% overall survival and 85-90% event-free survival.

The Equity Challenge in SCD Therapeutics

Sickle cell disease disproportionately affects Black and Hispanic populations, and the history of SCD care is marked by underinvestment relative to disease burden. The arrival of gene therapy is a scientific triumph, but the gap between scientific possibility and equitable access is vast. Gene therapy costs exceeding two million dollars, the requirement for specialized transplant centers, and the prolonged conditioning and recovery period create barriers that will exclude many of the patients who need these therapies most. For clinicians managing SCD in community settings, optimizing hydroxyurea — which remains dramatically underutilized — and ensuring access to the newer add-on therapies is the most impactful near-term priority while gene therapy access gradually expands.

Limitations and Unresolved Questions

The gene therapy data are transformative but early. Follow-up beyond two to three years is limited, and the long-term durability of HbF elevation, the true incidence of conditioning-related secondary malignancies, and the effects on fertility are still being characterized. Voxelotor's disconnect between hematologic improvement and clinical event reduction raises questions about whether hemoglobin level is the right surrogate endpoint for SCD therapeutic trials. And the STAND trial's failure to confirm crizanlizumab's VOC reduction benefit illustrates the challenge of translating promising Phase 2 results into definitive Phase 3 evidence in a disease with highly variable clinical course. For now, the treatment algorithm is clear in its principles — optimize hydroxyurea first, add targeted agents for residual disease burden, and refer appropriate candidates for gene therapy — even as the evidence base for individual components continues to evolve.

References

1. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia
2. Voxelotor in Sickle Cell Disease
3. Voxelotor in Sickle Cell Disease
4. Crizanlizumab for the Prevention of Pain Crises in Sickle Cell Disease
5. Lovotibeglogene autotemcel gene therapy for sickle cell disease
6. Exagamglogene autotemcel for sickle cell disease